Treatment selection preferences and barriers in relapsed or refractory large B-cell lymphoma.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Survey reveals provider preferences for CAR-T and bispecific antibodies in large B-cell lymphoma, indicating access barriers.

Providers showed a strong preference for CAR-T over bispecific antibodies based on perceived better outcomes.
Fifty-five percent cited perceived better outcomes as a reason for favoring CAR-T compared to logistical barriers for BsAb at specialized centers.
Treatment decisions were largely influenced by response rates, survival, and the toxicity profile rather than cost and logistical factors.
Access barriers remain a significant concern despite the preference for CAR-T, suggesting a need for improved healthcare resource management.

Gupta et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark